Table S4: DSST©, KSS, and SDS© scores

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Mean (SD) | Placebo  (N=54) | Daridorexant | | | |
| 5 mg  (N=56) | 10 mg  (N=54) | 25 mg  (N=55) | 50 mg  (N=56) |
| Total DSST© score |  |  |  |  |  |
| Baseline | 57.8 (15.4) | 58.4 (15.5) | 57.8 (15.4) | 57.9 (15.3) | 57.4 (15.3) |
| Change at Days 1&2 | 13.6 (9.8) | 12.9 (8.5) | 12.5 (8.1) | 12.2 (8.8) | 13.0 (11.2) |
| Total KSS score |  |  |  |  |  |
| Baseline | 5.1 (1.8) | 5.1 (1.8) | 5.1 (1.8) | 5.2 (1.8) | 5.1 (1.7) |
| Change at Days 1&2 | –0.7 (1.6) | –0.5 (1.6) | –0.8 (1.6) | –0.6 (1.5) | –0.6 (1.5) |
| Total SDS© score |  |  |  |  |  |
| Baseline | 10.7 (7.4) | 10.8 (7.9) | 10.7 (7.4) | 11.0 (7.8) | 10.8 (7.7) |
| Change at Days 1&2 | –2.7 (4.3) | –2.5 (3.8) | –2.6 (4.7) | –2.9 (3.9) | –2.6 (4.9) |

Days 1&2 refers to the mean value of the corresponding two PSG treatment nights for a given treatment period.

DSST©, Digit Symbol Substitution Test©; KSS, Karolinska Sleepiness Scale; SD, standard deviation; SDS©, Sheehan Disability Scale©.